To compare real-world persistence, effectiveness and tolerability of ustekinumab versus TNF inhibitors (TNFi) in psoriatic arthritis (PsA)
International audienceObjectives: To evaluate 6-month effectiveness of ustekinumab versus tumour nec...
OBJECTIVES: To compare treatment retention and response to secukinumab vs adalimumab, including the ...
This Italian multicenter retrospective study compared the drug survival and efficacy of different an...
To compare real-world persistence, effectiveness and tolerability of ustekinumab versus TNF inhibito...
Objectives To evaluate real-world persistence and effectiveness of the IL-12/23 inhibitor, ustekinum...
Objectives: To evaluate real-world persistence and effectiveness of the IL-12/23 inhibitor, ustekinu...
This study aims to evaluate the drug survival and effectiveness of ustekinumab in psoriatic arthriti...
The current prospective observational study aimed to evaluate the long-term (24 months), real-life e...
Objectives To evaluate 6-month effectiveness of ustekinumab versus tumour necrosis factor inhibitor ...
International audienceObjectives: To evaluate the characteristics of patients (pts) with PsA treated...
International audienceObjectives: To evaluate 6-month effectiveness of ustekinumab versus tumour nec...
OBJECTIVES: To compare treatment retention and response to secukinumab vs adalimumab, including the ...
This Italian multicenter retrospective study compared the drug survival and efficacy of different an...
To compare real-world persistence, effectiveness and tolerability of ustekinumab versus TNF inhibito...
Objectives To evaluate real-world persistence and effectiveness of the IL-12/23 inhibitor, ustekinum...
Objectives: To evaluate real-world persistence and effectiveness of the IL-12/23 inhibitor, ustekinu...
This study aims to evaluate the drug survival and effectiveness of ustekinumab in psoriatic arthriti...
The current prospective observational study aimed to evaluate the long-term (24 months), real-life e...
Objectives To evaluate 6-month effectiveness of ustekinumab versus tumour necrosis factor inhibitor ...
International audienceObjectives: To evaluate the characteristics of patients (pts) with PsA treated...
International audienceObjectives: To evaluate 6-month effectiveness of ustekinumab versus tumour nec...
OBJECTIVES: To compare treatment retention and response to secukinumab vs adalimumab, including the ...
This Italian multicenter retrospective study compared the drug survival and efficacy of different an...